Dengue Fever Treatment Market By Treatment Type (Vaccines, Symptomatic Drugs, Antiviral Drugs, Monoclonal Antibodies); By Route of Administration (Oral, Parenteral [Injectable]); By End User (Hospitals, Specialty Clinics, Home Healthcare); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Dengue Fever Treatment Market size was valued at USD 882.19 million in 2018 to USD 1,419.46 million in 2024 and is anticipated to reach USD 2,810.07 million by 2032, at a CAGR of 8.30% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2024
Forecast Period
2025-2032
Dengue Fever Treatment Market Size 2024
USD 1,419.46 Million
Dengue Fever Treatment Market, CAGR
8.30%
Dengue Fever Treatment Market Size 2032
USD 2,810.07 Million
The Dengue Fever Treatment Market is shaped by leading players such as Takeda Pharmaceutical, Sanofi, Pfizer, GlaxoSmithKline, Johnson & Johnson, Abbott Laboratories, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Cipla, Serum Institute of India, Bharat Biotech, Panacea Biotec, and Instituto Butantan. These companies strengthen their positions through vaccine innovations, development of monoclonal antibodies, and affordable symptomatic drug portfolios. Strategic collaborations with global health agencies and government partnerships enhance their market penetration, particularly in endemic regions. Asia Pacific emerged as the leading region with a 46% share in 2024, driven by high dengue prevalence, large-scale immunization initiatives, and significant investments in advanced therapies and preventive solutions.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The Dengue Fever Treatment Market grew from USD 882.19 million in 2018 to USD 1,419.46 million in 2024 and is expected to reach USD 2,810.07 million by 2032.
Asia Pacific led with 46% share in 2024, driven by high endemicity, large-scale vaccination programs, and rapid healthcare expansion across India, Indonesia, and the Philippines.
By treatment type, vaccines dominated with 38% share in 2024, followed by symptomatic drugs at 32%, highlighting their critical role in preventive and supportive care.
By route of administration, parenteral treatments held 61% share in 2024, reflecting the hospital-based delivery of vaccines, antivirals, and monoclonal antibodies.
Hospitals accounted for the highest end-user share at 54% in 2024, due to the need for inpatient care, intravenous therapy, and monitoring in severe dengue cases.
Market Segment Insights
By Treatment Type
Vaccines accounted for the largest share of the dengue fever treatment market with 38% in 2024. Their dominance is driven by growing adoption in endemic regions and government immunization initiatives. Symptomatic drugs held 32% share, supported by high patient reliance on pain relievers and antipyretics for immediate relief. Antiviral drugs represented 20% share, boosted by increasing R&D efforts to develop targeted therapies. Monoclonal antibodies captured 10% share, benefiting from recent clinical approvals that provide longer-term protection.
For instance, Dengvaxia was approved and integrated into national vaccination campaigns in countries like Brazil and the Philippines, the program was suspended and eventually banned in the Philippines due to safety risks in non-infected people.
By Route of Administration
Parenteral (injectable) treatments dominated the segment with 61% share in 2024. Their leadership stems from the necessity of hospital-based administration of vaccines, antivirals, and monoclonal antibodies. Oral treatments followed with 39% share, primarily driven by symptomatic drugs such as analgesics and fluid replacement therapies. The oral route continues to expand due to convenience, lower cost, and wider availability in outpatient and home healthcare settings.
For instance, by May 2024, Qdenga was approved in approximately 40 countries, not just “over 20”. Countries include Indonesia, Brazil, Thailand, Argentina, and members of the European Union.
By End User
Hospitals held the dominant position with 54% share in 2024, attributed to the need for inpatient care, intravenous drug administration, and critical monitoring in severe dengue cases. Specialty clinics accounted for 28% share, as they provide tailored treatments and follow-up services for dengue management. Home healthcare represented 18% share, supported by rising patient preference for oral symptomatic drugs and cost-effective care outside hospitals. Growing awareness and telehealth integration are expected to enhance adoption of home-based care in the coming years.
Key Growth Drivers
Rising Global Burden of Dengue
The increasing incidence of dengue cases worldwide serves as the strongest growth driver. According to WHO, nearly 390 million infections occur annually, intensifying the need for effective treatments. Governments in high-burden countries are expanding vector-control programs and allocating funds to strengthen treatment facilities. Hospitals and clinics report rising patient admissions during seasonal outbreaks, increasing reliance on both symptomatic and advanced therapies. This growing disease prevalence is pushing pharmaceutical companies to accelerate development of vaccines, antivirals, and supportive care solutions.
For instance, Takeda Pharmaceutical’s dengue vaccine, Qdenga, demonstrated 80.2% efficacy in Phase III trials across 8 countries, leading to its regulatory approval in Europe in December 2022
Advancements in Vaccine Development
Innovations in dengue vaccines are transforming the treatment landscape. Takeda’s Dengvaxia and Qdenga have gained approval across several regions, expanding patient access. The vaccines reduce hospitalization risk and severe dengue cases, driving higher demand in endemic regions. Public health agencies in Asia-Pacific and Latin America actively promote vaccination programs. Clinical pipelines for next-generation vaccines show promising outcomes, ensuring wider adoption over the next decade. The ability of vaccines to offer long-term prevention strengthens their role as a cornerstone in market expansion.
Government Support and Funding Initiatives
Robust government initiatives play a critical role in advancing dengue treatment availability. National immunization programs in countries like Brazil, Philippines, and India include dengue vaccines as part of public health policies. Funding support also extends to vector control measures, clinical trials, and procurement of medical supplies during outbreaks. Organizations such as UNICEF and WHO partner with governments to ensure affordable treatment access. These combined efforts not only boost awareness but also improve healthcare infrastructure, which directly accelerates treatment adoption across hospitals and community centers.
For instance, Brazil’s Ministry of Health launched a nationwide dengue control campaign in 2023 that distributed over 600,000 Wolbachia-infected mosquitoes to reduce dengue transmission.
Key Trends & Opportunities
Monoclonal Antibody Therapies
The rise of monoclonal antibodies offers new opportunities in dengue management. These therapies provide targeted immune protection, reducing viral load and disease severity. Recent clinical trials highlight efficacy against multiple dengue strains, making them a promising segment for long-term treatment strategies. Growing pharmaceutical partnerships and accelerated regulatory approvals are pushing these therapies into mainstream adoption. High acceptance among patients with severe infections and supportive reimbursement policies are expected to position monoclonal antibodies as a major future growth driver in the market.
For instance, Janssen Pharmaceuticals (Johnson & Johnson) partnered with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate its mAb combination therapy, including antibodies JNJ-1802 and JNJ-1954, which showed a greater than 90% reduction in viral RNA in non-human primate models within 48 hours of administration.
Expansion of Home Healthcare and Telemedicine
Home healthcare adoption is growing as patients prefer cost-effective treatment outside hospitals. Oral symptomatic drugs, fluid replacement, and remote monitoring technologies are supporting this transition. Telemedicine platforms enable patients to consult physicians for early symptom management, reducing hospitalization pressure. This trend is especially evident in Asia-Pacific, where digital health adoption is rapidly increasing. Pharmaceutical companies and digital health providers are collaborating to integrate telehealth tools with dengue care solutions. The expansion of this model represents a strong opportunity for widening access to treatment.
For instance, Takeda’s tetravalent dengue vaccine candidate, TAK-003, is based on a live, attenuated dengue serotype 2 virus that provides cross-neutralizing activity against all four dengue serotypes. Phase 3 data from a 4.5-year study showed a cumulative vaccine efficacy of 84.1% against hospitalized dengue.
Key Challenges
Limited Antiviral Options
The absence of widely approved, effective antiviral drugs remains a major hurdle. While research is ongoing, most treatments remain symptomatic, leaving patients reliant on supportive care. This limitation increases hospitalization duration and recovery times. Uncertainty in clinical trial outcomes also discourages large-scale investments from pharmaceutical companies. Without breakthrough therapies, reliance on vaccines and symptomatic drugs continues, slowing innovation. Developing effective antivirals that cover all dengue serotypes is a critical need for strengthening the treatment market’s long-term growth potential.
Vaccine Safety Concerns and Acceptance
Safety concerns around dengue vaccines have created barriers to adoption. Previous controversies, such as limited efficacy in seronegative patients, have raised public skepticism. Despite advancements, some regions remain hesitant to include vaccines in mass immunization programs. Negative public perception affects uptake rates and slows revenue growth for manufacturers. Addressing safety profiles through transparent clinical data and public education campaigns is essential to restore trust. Without higher acceptance, the full preventive potential of vaccines may not be realized, limiting overall market progress.
High Treatment Costs in Developing Regions
Affordability continues to challenge access in low- and middle-income countries, where dengue is most prevalent. Vaccines, monoclonal antibodies, and advanced therapies often remain priced beyond the reach of average households. Weak reimbursement systems and uneven healthcare funding further worsen disparities in treatment availability. Many patients rely on low-cost symptomatic drugs, which provide only temporary relief. Unless manufacturers and governments collaborate on cost-reduction measures, equitable access will remain limited. This cost challenge directly affects both patient outcomes and market penetration in developing regions.
Regional Analysis
North America
North America accounted for 22% of the global dengue fever treatment market in 2024, with revenue of USD 229.68 million. The region is projected to reach USD 458.07 million by 2032, growing at a CAGR of 8.4%. Strong healthcare infrastructure, high awareness levels, and adoption of advanced therapies such as monoclonal antibodies drive market growth. The U.S. leads regional demand with expanded vaccine approvals and government-led awareness campaigns. Increasing cross-border travel also amplifies the need for preventive and therapeutic solutions, strengthening North America’s role in the global landscape.
Europe
Europe represented 17% of the market share in 2024, valued at USD 177.44 million, and is projected to reach USD 306.32 million by 2032 at a CAGR of 6.4%. The region benefits from structured healthcare systems and rising incidence of travel-related dengue cases. Countries like France, Spain, and Italy report higher adoption of vaccines and supportive care. Government efforts to monitor vector-borne diseases and collaborations with pharmaceutical companies are expanding access to advanced treatments. However, slower adoption compared to Asia-Pacific reflects reliance on preventive measures and relatively lower prevalence rates.
Asia Pacific
Asia Pacific dominated the market with the largest 46% share in 2024, generating USD 615.47 million and expected to reach USD 1,296.09 million by 2032 at a CAGR of 9.1%. The region’s dominance stems from high endemicity in countries such as India, Indonesia, and the Philippines, which account for a majority of global dengue cases. Large-scale vaccination programs, government investments, and a surge in R&D for antivirals strengthen market growth. Rapid healthcare expansion and growing awareness further drive treatment adoption. Asia Pacific remains the most critical region for future market expansion due to its significant disease burden.
Latin America
Latin America held 26% of the global market share in 2024, valued at USD 350.42 million, and is projected to reach USD 678.66 million by 2032 at a CAGR of 8.0%. Brazil and Argentina lead regional demand, supported by widespread dengue prevalence and government immunization initiatives. The high adoption of vaccines and symptomatic drugs highlights the region’s urgent need for effective solutions. Seasonal outbreaks and large-scale awareness campaigns boost demand across hospitals and clinics. Latin America’s strong disease burden ensures it remains a vital market for pharmaceutical companies expanding treatment portfolios.
Middle East
The Middle East accounted for 2% share in 2024, valued at USD 28.45 million, with projections reaching USD 45.08 million by 2032 at a CAGR of 5.3%. Although the disease burden is lower compared to Asia and Latin America, rising travel-related cases and imported infections drive demand. Countries in the GCC are investing in vaccines and advanced therapies as precautionary measures. Growing public health initiatives and collaborations with international pharmaceutical firms support gradual market expansion. However, limited endemic presence keeps market size relatively modest.
Africa
Africa captured 1% of the market share in 2024, valued at USD 18.00 million, and is projected to reach USD 25.85 million by 2032 at a CAGR of 4.0%. Dengue remains underreported in many African nations due to weak surveillance systems and limited diagnostic infrastructure. However, rising outbreaks in regions like East Africa are creating awareness and increasing demand for symptomatic care. Access challenges, affordability issues, and fragmented healthcare systems constrain growth. International collaborations and government-backed vaccination efforts are expected to improve treatment adoption gradually across the region.
Market Segmentations:
By Treatment Type
Vaccines
Symptomatic Drugs
Antiviral Drugs
Monoclonal Antibodies
By Route of Administration
Oral
Parenteral (Injectable)
By End User
Hospitals
Specialty Clinics
Home Healthcare
By Region
North America:S., Canada, Mexico
Europe:UK, France, Germany, Italy, Spain, Russia, Rest of Europe
Asia Pacific:China, Japan, South Korea, India, Australia, Southeast Asia, Rest of Asia Pacific
Latin America:Brazil, Argentina, Rest of Latin America
Middle East:GCC Countries, Israel, Turkey, Rest of Middle East
Africa:South Africa, Egypt, Rest of Africa
Competitive Landscape
The dengue fever treatment market is moderately consolidated, with global and regional players competing through product innovation, vaccine approvals, and strategic collaborations. Leading companies such as Takeda Pharmaceutical, Sanofi, Pfizer, and GlaxoSmithKline dominate with strong vaccine portfolios and global distribution networks. Their market strength is reinforced by continuous R&D investment, clinical trials for advanced antivirals, and regulatory approvals across endemic regions. Generic drug manufacturers including Sun Pharmaceutical, Teva, and Dr. Reddy’s Laboratories play a vital role by supplying affordable symptomatic drugs widely used in hospitals and home healthcare. Emerging biopharma firms are focusing on monoclonal antibodies and next-generation antivirals, supported by funding from governments and international health agencies. Strategic partnerships, such as collaborations with the WHO and UNICEF for vaccine distribution, strengthen market penetration in Asia-Pacific and Latin America. Competition is also intensifying through pricing strategies, expansion into developing regions, and technology-driven innovations in diagnostics and treatment delivery.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In June 2025, the Serum Institute of India partnered with DNDi to advance a monoclonal antibody treatment targeting all four dengue virus serotypes, moving into Phase III clinical trials across India, Brazil, and other endemic regions.
In August 2024, Panacea Biotec, in collaboration with ICMR, initiated a Phase III trial for its dengue vaccine candidate DengiAll in India.
In February 2024, Takeda Pharmaceutical announced a manufacturing partnership with Biological E. Ltd., scaling production capacity for QDENGA (TAK-003) to 50 million doses annually, with a target of 100 million by 2030.
Report Coverage
The research report offers an in-depth analysis based on Tretament Type, Route of Administration, End User and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Demand for dengue vaccines will continue to expand in endemic regions.
Pharmaceutical companies will accelerate development of effective antiviral therapies.
Monoclonal antibodies will gain wider acceptance for severe case management.
Governments will strengthen immunization programs to reduce hospitalization rates.
Digital health and telemedicine will improve access to early diagnosis and treatment.
Home healthcare solutions will see rising adoption for mild and moderate cases.
Public–private partnerships will drive faster distribution of vaccines and therapies.
Research collaborations will focus on next-generation multivalent vaccines.
Awareness campaigns will enhance preventive care and early intervention practices.
Market players will expand presence in Asia-Pacific and Latin America to meet rising demand.
CHAPTER NO. 1: GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries CHAPTER NO. 2: EXECUTIVE LENS
2.1 Pulse of the Industry – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Million)
2.3. Premium Insights – Based on Primary Interviews CHAPTER NO. 3: DENGUE FEVER TREATMENT MARKET FORCES & INDUSTRY PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
3.6 Price Trend Analysis
3.6.1 Regional Price Trend
3.6.2 Price Trend by Product CHAPTER NO. 4: KEY INVESTMENT EPICENTER
4.1 Regional Goldmines – High-Growth Geographies
4.2 Product Frontiers – Lucrative Product Categories
4.3 Application Sweet Spots – Emerging Demand Segments CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Regional Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Treatment Type & End User Revenue CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS
6.1. Import Analysis by Region
6.1.1. Global Dengue Fever Treatment Import Revenue By Region
6.2. Export Analysis by Region
6.2.1. Global Dengue Fever Treatment Export Revenue By Region CHAPTER NO. 7: COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Global Dengue Fever Treatment: Company Market Share
7.2. Global Dengue Fever Treatment Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Product Launch
7.3.3. Regional Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024 CHAPTER NO. 8: DENGUE FEVER TREATMENT MARKET – BY TREATMENT TYPE SEGMENT ANALYSIS
8.1. Dengue Fever Treatment Overview by Treatment Type Segment
8.1.1. Dengue Fever Treatment Revenue Share By Treatment Type
8.2. Vaccines
8.3. Symptomatic Drugs
8.4. Antiviral Drugs
8.5. Monoclonal Antibodies CHAPTER NO. 9: DENGUE FEVER TREATMENT MARKET – BY ROUTE OF ADMINISTRATION SEGMENT ANALYSIS
9.1. Dengue Fever Treatment Overview by Route of Administration Segment
9.1.1. Dengue Fever Treatment Revenue Share By Route of Administration
9.2. Oral
9.3. Parenteral (Injectable) CHAPTER NO. 10: DENGUE FEVER TREATMENT MARKET – BY END USER SEGMENT ANALYSIS
10.1. Dengue Fever Treatment Overview by End User Segment
10.1.1. Dengue Fever Treatment Revenue Share By End User
10.2. Hospitals
10.3. Specialty Clinics
10.4. Home Healthcare CHAPTER NO. 11: DENGUE FEVER TREATMENT MARKET – REGIONAL ANALYSIS
11.1. Dengue Fever Treatment Overview by Region Segment
11.1.1. Global Dengue Fever Treatment Revenue Share By Region
11.1.2. Regions
11.1.3. Global Dengue Fever Treatment Revenue By Region
11.1.4. Treatment Type
11.1.5. Global Dengue Fever Treatment Revenue By Treatment Type
11.1.6. Route of Administration
11.1.7. Global Dengue Fever Treatment Revenue By Route of Administration
11.1.8. End User
11.1.9. Global Dengue Fever Treatment Revenue By End User CHAPTER NO. 12: NORTH AMERICA DENGUE FEVER TREATMENT MARKET – COUNTRY ANALYSIS
12.1. North America Dengue Fever Treatment Overview by Country Segment
12.1.1. North America Dengue Fever Treatment Revenue Share By Region
12.2. North America
12.2.1. North America Dengue Fever Treatment Revenue By Country
12.2.2. Treatment Type
12.2.3. North America Dengue Fever Treatment Revenue By Treatment Type
12.2.4. Route of Administration
12.2.5. North America Dengue Fever Treatment Revenue By Route of Administration
12.2.6. End User
12.2.7. North America Dengue Fever Treatment Revenue By End User
2.3. U.S.
12.4. Canada
12.5. Mexico CHAPTER NO. 13: EUROPE DENGUE FEVER TREATMENT MARKET – COUNTRY ANALYSIS
13.1. Europe Dengue Fever Treatment Overview by Country Segment
13.1.1. Europe Dengue Fever Treatment Revenue Share By Region
13.2. Europe
13.2.1. Europe Dengue Fever Treatment Revenue By Country
13.2.2. Treatment Type
13.2.3. Europe Dengue Fever Treatment Revenue By Treatment Type
13.2.4. Route of Administration
13.2.5. Europe Dengue Fever Treatment Revenue By Route of Administration
13.2.6. End User
13.2.7. Europe Dengue Fever Treatment Revenue By End User
13.3. UK
13.4. France
13.5. Germany
13.6. Italy
13.7. Spain
13.8. Russia
13.9. Rest of Europe CHAPTER NO. 14: ASIA PACIFIC DENGUE FEVER TREATMENT MARKET – COUNTRY ANALYSIS
14.1. Asia Pacific Dengue Fever Treatment Overview by Country Segment
14.1.1. Asia Pacific Dengue Fever Treatment Revenue Share By Region
14.2. Asia Pacific
14.2.1. Asia Pacific Dengue Fever Treatment Revenue By Country
14.2.2. Treatment Type
14.2.3. Asia Pacific Dengue Fever Treatment Revenue By Treatment Type
14.2.4. Route of Administration
14.2.5. Asia Pacific Dengue Fever Treatment Revenue By Route of Administration
14.2.5. End User
14.2.7. Asia Pacific Dengue Fever Treatment Revenue By End User
14.3. China
14.4. Japan
14.5. South Korea
14.6. India
14.7. Australia
14.8. Southeast Asia
14.9. Rest of Asia Pacific CHAPTER NO. 15: LATIN AMERICA DENGUE FEVER TREATMENT MARKET – COUNTRY ANALYSIS
15.1. Latin America Dengue Fever Treatment Overview by Country Segment
15.1.1. Latin America Dengue Fever Treatment Revenue Share By Region
15.2. Latin America
15.2.1. Latin America Dengue Fever Treatment Revenue By Country
15.2.2. Treatment Type
15.2.3. Latin America Dengue Fever Treatment Revenue By Treatment Type
15.2.4. Route of Administration
15.2.5. Latin America Dengue Fever Treatment Revenue By Route of Administration
15.2.6. End User
15.2.7. Latin America Dengue Fever Treatment Revenue By End User
15.3. Brazil
15.4. Argentina
15.5. Rest of Latin America CHAPTER NO. 16: MIDDLE EAST DENGUE FEVER TREATMENT MARKET – COUNTRY ANALYSIS
16.1. Middle East Dengue Fever Treatment Overview by Country Segment
16.1.1. Middle East Dengue Fever Treatment Revenue Share By Region
16.2. Middle East
16.2.1. Middle East Dengue Fever Treatment Revenue By Country
16.2.2. Treatment Type
16.2.3. Middle East Dengue Fever Treatment Revenue By Treatment Type
16.2.4. Route of Administration
16.2.5. Middle East Dengue Fever Treatment Revenue By Route of Administration
16.2.6. End User
16.2.7. Middle East Dengue Fever Treatment Revenue By End User
16.3. GCC Countries
16.4. Israel
16.5. Turkey
16.6. Rest of Middle East CHAPTER NO. 17: AFRICA DENGUE FEVER TREATMENT MARKET – COUNTRY ANALYSIS
17.1. Africa Dengue Fever Treatment Overview by Country Segment
17.1.1. Africa Dengue Fever Treatment Revenue Share By Region
17.2. Africa
17.2.1. Africa Dengue Fever Treatment Revenue By Country
17.2.2. Treatment Type
17.2.3. Africa Dengue Fever Treatment Revenue By Treatment Type
17.2.4. Route of Administration
17.2.5. Africa Dengue Fever Treatment Revenue By Route of Administration
17.2.6. End User
17.2.7. Africa Dengue Fever Treatment Revenue By End User
17.3. South Africa
17.4. Egypt
17.5. Rest of Africa CHAPTER NO. 18: COMPANY PROFILES
18.1. Pfizer
18.1.1. Company Overview
18.1.2. Product Portfolio
18.1.3. Financial Overview
18.1.4. Recent Developments
18.1.5. Growth Strategy
18.1.6. SWOT Analysis
18.2. GlaxoSmithKline
18.3. Teva Pharmaceuticals
18.4. Mylan
18.5. Sun Pharmaceutical Industries
18.6. Perrigo Company
18.7. Fresenius Kabi
18.8. Others
Request Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Dengue Fever Treatment Market, and what is its projected size in 2032?
The Dengue Fever Treatment Market reached USD 1,419.46 million in 2024 and is projected to attain USD 2,810.07 million by 2032, reflecting consistent global demand.
At what Compound Annual Growth Rate is the Dengue Fever Treatment Market projected to grow between 2025 and 2032?
The Dengue Fever Treatment Market is forecast to expand at a CAGR of 8.30% during the period 2025–2032, supported by vaccines, antivirals, and government initiatives.
Which Dengue Fever Treatment Market segment held the largest share in 2024?
In 2024, vaccines dominated with 38% share, followed by symptomatic drugs at 32%, reflecting widespread adoption through immunization programs and preventive healthcare strategies worldwide.
What are the primary factors fueling the growth of the Dengue Fever Treatment Market?
Key drivers include the rising global burden of dengue, advancements in vaccine development, and government funding initiatives promoting widespread treatment and prevention access.
Who are the leading companies in the Dengue Fever Treatment Market?
Prominent players include Takeda Pharmaceutical, Sanofi, Pfizer, GlaxoSmithKline, Sun Pharma, Teva, Dr. Reddy’s, Cipla, Serum Institute, and Bharat Biotech, shaping global competition.
Which region commanded the largest share of the Dengue Fever Treatment Market in 2024?
Asia Pacific led with 46% share in 2024, driven by high disease prevalence, vaccination programs, strong government support, and growing adoption of advanced therapies.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Global Nutraceutical Ingredients Market size was valued at USD 63,746.9 million in 2018 to USD 87,650.2 million in 2024 and is anticipated to reach USD 126,749.2 million by 2032, at a CAGR of 4.69% during the forecast period
The Global Gout Therapeutics Market size was valued at USD 1,440.6 million in 2018 to USD 2,215.5 million in 2024 and is anticipated to reach USD 3,613.6 million by 2032, at a CAGR of 6.26% during the forecast period.
The Global Digital Sphygmomanometer Market size was valued at USD 1,764.9 million in 2018 to USD 2,642.3 million in 2024 and is anticipated to reach USD 4,495.6 million by 2032, at a CAGR of 6.89% during the forecast period.
Mycelium Based Packaging Market size was valued at USD 420 million in 2024 and is anticipated to reach USD 1047.4 million by 2032, at a CAGR of 12.1% during the forecast period.
Multi Touch Equipment Market size was valued at USD 20.5 billion in 2024 and is anticipated to reach USD 43.2 billion by 2032, at a CAGR of 9.8% during the forecast period.
Multi Split Air Conditioning Systems Market size was valued at USD 22.3 billion in 2024 and is anticipated to reach USD 32 billion by 2032, at a CAGR of 4.6% during the forecast period.
The robotic combat vehicles market size was valued at USD 701.8 million in 2024 and is anticipated to reach USD 1179 million by 2032, at a CAGR of 6.7 % during the forecast period (2024-2032).
The robot end effector market size was valued at USD 3,330 million in 2024 and is anticipated to reach USD 8145.4 million by 2032, at a CAGR of 11.8 % during the forecast period (2024-2032).
The robotic pool cleaner market size was valued at USD 2,220 million in 2024 and is anticipated to reach USD 5061 million by 2032, at a CAGR of 10.9 % during the forecast period (2024-2032).
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
